Wai Yuen Tong Medicine Holdings Limited (HKG:0897)
0.3550
0.00 (0.00%)
At close: Feb 13, 2026
HKG:0897 Revenue
Wai Yuen Tong Medicine Holdings had revenue of 322.82M HKD in the half year ending September 30, 2025, a decrease of -12.36%. This brings the company's revenue in the last twelve months to 721.27M, down -6.71% year-over-year. In the fiscal year ending March 31, 2025, Wai Yuen Tong Medicine Holdings had annual revenue of 745.30M, down -4.92%.
Revenue (ttm)
721.27M
Revenue Growth
-6.71%
P/S Ratio
0.55
Revenue / Employee
993.49K
Employees
726
Market Cap
399.41M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 745.30M | -38.58M | -4.92% |
| Mar 31, 2024 | 783.88M | 60.28M | 8.33% |
| Mar 31, 2023 | 723.60M | -667.81M | -48.00% |
| Mar 31, 2022 | 1.39B | 282.85M | 25.51% |
| Mar 31, 2021 | 1.11B | 487.82M | 78.59% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zhongzhi Pharmaceutical Holdings | 2.20B |
| Lee's Pharmaceutical Holdings | 1.44B |
| Shenzhen Neptunus Interlong Bio-technique Company | 1.09B |
| PuraPharm Corporation | 346.76M |
| Tianda Pharmaceuticals | 310.50M |
| Fusen Pharmaceutical Company | 264.08M |
| Pak Fah Yeow International | 199.55M |
| Extrawell Pharmaceutical Holdings | 52.65M |